Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer

Molecular Pharmacology

Volumn 80, Issue 4, 2011, Pages 598-609

  Kovacevic, Zaklina ^a   Chikhani, Sherin ^a   Lovejoy, David B ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEFEROXAMINE MESYLATE; DI 2 PYRIDYLKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE HYDROCHLORIDE; FLUOROURACIL; GEMCITABINE; IRON CHELATING AGENT; SERINE; THIOSEMICARBAZONE DERIVATIVE; THREONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GENE; GENE EXPRESSION; HEMATOLOGY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; IRON CHELATING AGENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; THIOSEMICARBAZONES; TREATMENT OUTCOME; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053198672     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.073627     Document Type: Article

References (40)

1. Angst E, Sibold S, Tiffon C, Weimann R, Gloor B, Candinas D, and Stroka D (2006) Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer 95:307-313. (Pubitemid 44187591)
2. Aouad F, Florence A, Zhang Y, Collins F, Henry C, Ward RJ, and Crichton RR (2002) Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339:470-480.
3. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, and Holen KD (2008) A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26:369-379.
4. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, Ménard S, and Pratesi G (2004) Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 40:1275-1281. (Pubitemid 38526349)
5. Buss JL, Torti FM, and Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021-1034. (Pubitemid 36582246)
6. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, and Sherr CJ (1999) The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571-1583. (Pubitemid 29127070)
7. Custodio A, Puente J, Sastre J, and Díaz-Rubio E (2009) Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev 35:676-684.
8. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, et al. (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773:1095-1106. (Pubitemid 46898677)
9. Dunn LL, Sekyere EO, Rahmanto YS, and Richardson DR (2006) The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis 27:2157-2169. (Pubitemid 44644804)
10. Ellen TP, Ke Q, Zhang P, and Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29:2-8. (Pubitemid 351201735)
11. Fu D and Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752-761. (Pubitemid 47105414)
12. Furukawa T (2009) Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol Hepatol 7 (11 Suppl):S35-S39.
13. Gao J and Richardson DR (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98:842-850.
14. Jansson PJ, Sharpe PC, Bernhardt PV, and Richardson DR (2010) Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 53:5759-5769.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
16. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583. (Pubitemid 43036441)
17. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, and Korc M (1998) Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 55:363-369. (Pubitemid 28279682)
18. Kovacevic Z, Fu D, and Richardson DR (2008) The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta 1783:1981-1992.
19. Kovacevic Z and Richardson DR (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355-2366. (Pubitemid 44884092)
20. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, and Richardson DR (2011) The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 32:732-740.
21. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, and Aggarwal BB (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67:3853-3861. (Pubitemid 46762173)
22. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, and Benson AB 3rd (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101:587-592.
23. Laquente B, Lacasa C, Ginestà MM, Casanovas O, Figueras A, Galán M, Ribas IG, Germà JR, Capellà G, and Viñals F (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7:638-647. (Pubitemid 351482146)
24. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975. (Pubitemid 39434989)
25. Mackenzie MJ, Saltman D, Hirte H, Low J, Johnson C, Pond G, and Moore MJ (2007) A phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital phase II consortium. Invest New Drugs 25:553-558.
26. Maruyama Y, Ono M, Kawahara A, Yokoyama T, Basaki Y, Kage M, Aoyagi S, Kinoshita H, and Kuwano M (2006) Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res 66:6233-6242.
27. Murakami Y, Hosoi F, Izumi H, Maruyama Y, Ureshino H, Watari K, Kohno K, Kuwano M, and Ono M (2010) Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem Biophys Res Commun 396:376-381.
28. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, Peggie M, Bain J, Bloomberg GB, Grahammer F, et al. (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 384:477-488. (Pubitemid 40018961)
29. Nurtjahja-Tjendraputra E, Fu D, Phang JM, and Richardson DR (2007) Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiencymediated growth suppression. Blood 109:4045-4054. (Pubitemid 46641760)
30. Réjiba S, Bigand C, Parmentier C, and Hajri A (2009) Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 11:637-650.
31. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, and Lovejoy DB (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 1790:702-717.
32. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49:6510-6521. (Pubitemid 44657445)
33. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
34. Scovill JP (1990) A facile synthesis of thiosemicarbazides and thiosemicarbazones by the transamination of 4-methyl-4-phenyl-3- thiosemicarbazine. Phosphorus Sulfur Silicon Relat Elem 60:15-19.
35. Stein S, Thomas EK, Herzog B, Westfall MD, Rocheleau JV, Jackson RS, 2nd, Wang M, and Liang P (2004) NDRG1 is necessary for p53-dependent apoptosis. J Biol Chem 279:48930-48940. (Pubitemid 39625774)
36. Tang DG and Porter AT (1996) Apoptosis: a current molecular analysis. Pathol Oncol Res 2:117-131.
37. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906. (Pubitemid 44527826)
38. Wong A, Soo RA, Yong WP, and Innocenti F (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41:77-88.
39. Yu Y, Kovacevic Z, and Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6:1982-1994. (Pubitemid 47327885)
40. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458. (Pubitemid 39166524)